연부조직 감염 진료지침 권고안

키워드

참고문헌 (167)

1. 대한감염학회, "심혈관계 감염 진료지침 권고안", Infection and Chemotherapy, 43(2), pp.129~177 (2011), 대한감염학회
2. Ferrieri P., "Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci", J Clin Invest, 51, pp.2851~2862 (1972)
3. Adams BB., "Dermatologic disorders of the athlete", Sports Med, 32, pp.309~321 (2002)
4. Fehrs LJ., "Group A beta-hemolytic streptococcal skin infections in a US meat-packing plant", JAMA, 258, pp.3131~3134 (1987)
5. Hirschmann JV., "Impetigo : etiology and therapy", Curr Clin Top Infect Dis, 22, pp.42~51 (2002)
6. Darmstadt GL., "Impetigo : an overview", Pediatr Dermatol, 11, pp.293~303 (1994)
7. Demidovich CW., "Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies", Am J Dis Child, 144, pp.1313~1315 (1990)
8. 박지혜, "지난 11년간 5년 간격으로 살펴본 피부과 외래 환자의 피부 세균 감염의 변화 추세", 대한피부과학회지, 47(6), pp.690~695 (2009), 대한피부과학회
9. Park SW., "A study for the isolation of the causative organism, antimicrobial susceptibility tests and therapeutic aspects in patients with impetigo", Korean J Dermatol, 31, pp.312~319 (1993)
10. Kaplan EL., "Suppression of the antistreptolysin O response by cholesterol and by lipid extracts of rabbit skin", J Exp Med, 144, pp.754~767 (1976)
11. Bisno AL., "Factors influencing serum antibody responses in streptococcal pyoderma", J Lab Clin Med, 81, pp.410~420 (1973)
12. Kaplan EL., "The influence of the site of infection on the immune response to group A streptococci", J Clin Invest, 49, pp.1405~1414 (1970)
13. Derrick CW Jr., "Impetigo contagiosa", Am Fam Physician, 4, pp.75~81 (1971)
14. Ferrieri P., "A controlled study of penicillin prophylaxis against streptococcal impetigo", J Infect Dis, 129, pp.429~438 (1974)
15. Barton LL., "Impetigo : a reassessment of etiology and therapy", Pediatr Dermatol, 4, pp.185~188 (1987)
16. Dagan R., "Comparison of amoxicillin and clavulanic acid(augmentin)for the treatment of nonbullous impetigo", Am J Dis Child, 143, pp.916~918 (1989)
17. Barton LL., "Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin", Pediatr Dermatol, 6, pp.134~138 (1989)
18. Britton JW., "Comparison of mupirocin and erythromycin in the treatment of impetigo", J Pediatr, 117, pp.827~829 (1990)
19. Yun HJ., "Prevalence and mechanisms of low-and high-level mupirocin resistance in staphylococci isolated from a Korean hospital", J Antimicrob Chemother, 51, pp.619~623 (2003)
20. Vila J., "Are quinolone-resistant uropathogenic Escherichia coli less virulent?", J Infect Dis, 186, pp.1039~1042 (2002)
21. Decker MD., "An outbreak of staphylococcal skin infections among river rafting guides", Am J Epidemiol, 124, pp.969~976 (1986)
22. Sosin DM., "An outbreak of furunculosis among high school athletes", Am J Sports Med, 17, pp.828~832 (1989)
23. Zimakoff J., "Recurrent staphylococcal furunculosis in families", Scand J Infect Dis, 20, pp.403~405 (1988)
24. Hedstrom SA., "Recurrent staphylococcal furunculosis. Bacteriological findings and epidemiology in 100 cases", Scand J Infect Dis, 13, pp.115~119 (1981)
25. Raz R., "A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection", Arch Intern Med, 156, pp.1109~1112 (1996)
26. Lipsky BA., "Immediate and long-term efficacy of systemic antibiotics for eradicating nasal colonization with Staphylococcus aureus", Eur J Clin Microbiol Infect Dis, 11, pp.43~47 (1992)
27. Klempner MS., "Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy", JAMA, 260, pp.2682~2685 (1988)
28. Bisno AL., "Streptococcal infections of skin and soft tissues", N Engl J Med, 334, pp.240~245 (1996)
29. Chartier C., "Erysipelas", Int J Dermatol, 29, pp.459~467 (1990)
30. Chartier C., "Erysipelas : an update", Int J Dermatol, 35, pp.779~781 (1996)
31. 곽이경, "단독과 연조직염의 임상적 특성과 원인균에 관한 연구", Infection and Chemotherapy, 44(2), pp.45~50 (2012), 대한감염학회[DOI]
32. Morris AD., "Cellulitis and erysipelas", Clin Evid (Online), pii 1708, ~ (2008)
33. Stevens DL., "Practice guidelines for the diagnosis and management of skin and soft-tissue infections", Clin Infect Dis, 41, pp.1373~1406 (2005)
34. Bernard P., "Roxithromycin versus penicillin in the treatment of erysipelas in adults : a comparative study", Br J Dermatol, 127, pp.155~159 (1992)
35. Martin JM., "Erythromycinresistant group A streptococci in schoolchildren in Pittsburgh", N Engl J Med, 346, pp.1200~1206 (2002)
36. 서용수, "Changing Molecular Epidemiology of Group B Streptococcus in Korea", Journal of Korean Medical Science, 25(6), pp.817~823 (2010), 대한의학회
37. Koh EH., "Decrease of erythromycin resistance in group A streptococci by change of emm distribution", Jpn J Infect Dis, 61, pp.261~263 (2008)
38. 김효열, "Macrolide Resistance in B-Hemolytic Streptococci: Changes after the Implementation of the Separation of Prescribing and Dispensing of Medications Policy in Korea", Yonsei Medical Journal, 45(4), pp.591~597 (2004), 연세대학교의과대학
39. 어영, "Macrolide Resistance Trends in β-Hemolytic Streptococci in a Tertiary Korean Hospital", Yonsei Medical Journal, 48(5), pp.773~778 (2007), 연세대학교의과대학
40. Dupuy A., "Risk factors for erysipelas of the leg(cellulitis) : case-control study", BMJ, 318, pp.1591~1594 (1999)
41. Baddour LM., "Recurrent cellulitis after saphenous venectomy for coronary bypass surgery", Ann Intern Med, 97, pp.493~496 (1982)
42. Simon MS., "Cellulitis after axillary lymph node dissection for carcinoma of the breast", Am J Med, 93, pp.543~548 (1992)
43. Dankert J., "Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy", Br J Obstet Gynaecol, 94, pp.788~790 (1987)
44. Bernard P., "Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique", Arch Dermatol, 125, pp.779~782 (1989)
45. Perl B., "Cost-effectiveness of blood cultures for adult patients with cellulitis", Clin Infect Dis, 29, pp.1483~1488 (1999)
46. Kielhofner MA., "Influence of underlying disease process on the utility of cellulitis needle aspirates", Arch Intern Med, 148, pp.2451~2452 (1988)
47. Hook EW 3rd., "Microbiologic evaluation of cutaneous cellulitis in adults", Arch Intern Med, 146, pp.295~297 (1986)
48. Sachs MK., "The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults", Arch Intern Med, 150, pp.1907~1912 (1990)
49. Duvanel T., "Quantitative cultures of biopsy specimens from cutaneous cellulitis", Arch Intern Med, 149, pp.293~296 (1989)
50. Woo PC., "Cellulitis complicating lymphoedema", Eur J Clin Microbiol Infect Dis, 19, pp.294~297 (2000)
51. Grayson ML., "Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderateto-severe cellulitis in adults", Clin Infect Dis, 34, pp.1440~1448 (2002)
52. Chan JC., "Ampicillin", sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology, 1995, pp.12, 139~146
53. Muijsers RB., "Moxifloxacin in uncomplicated skin and skin structure infections", Drugs, 62, pp.967~973 (2002)
54. Hepburn MJ., "Comparison of short-course(5 days)and standard(10 days)treatment for uncomplicated cellulitis", Arch Intern Med, 164, pp.1669~1674 (2004)
55. Kremer M., "Long-term antimicrobial therapy in the prevention of recurrent softtissue infections", J Infect, 22, pp.37~40 (1991)
56. Wang JH., "Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs", Clin Infect Dis, 25, pp.685~689 (1997)
57. Sarani B., "Necrotizing fasciitis : current concepts and review of the literature", J Am Coll Surg, 208, pp.279~288 (2009)
58. Ellis Simonsen SM., "Cellulitis incidence in a defined population", Epidemiol Infect, 134, pp.293~299 (2006)
59. Angoules AG., "Necrotising fasciitis of upper and lower limb: a systematic review", Injury, 38(Suppl 5)), pp.S19~S26 (2007)
60. Howell GM., "Necrotizing soft tissue infections", Surg Infect(Larchmt), 12, pp.185~190 (2011)
61. Cainzos M., "Necrotizing soft tissue infections", Curr Opin Crit Care, 13, pp.433~439 (2007)
62. Morgan MS., "Diagnosis and management of necrotising fasciitis : a multiparametric approach", J Hosp Infect, 75, pp.249~257 (2010)
63. Ustin JS., "Necrotizing soft-tissue infections", Crit Care Med, 39, pp.2156~2162 (2011)
64. Cho JP., "Necrotizing fasciitis : a clinical review", Korean J Trauma, 6, pp.38~43 (1993)
65. Lee JH., "Necrotizing fasciitis", J Korean Surg Soc, 27, pp.261~269 (1984)
66. 이성태, "하지에 발생한 괴사성 근막염", 대한정형외과학회지, 40(6), pp.772~777 (2005), 대한정형외과학회
67. 이민우, "국내 세 개 대학 병원에서 괴사성 근막염의 특징", 대한내과학회지, 70(6), pp.681~687 (2006), 대한내과학회
68. 양윤수, "경부에 발생한 괴사성 근막염에 대한 임상적 고찰", 대한이비인후과학회지 두경부외과학, 48(8), pp.1020~1026 (2005), 대한이비인후과학회
69. Park JH., "Clinical analysis of Fournier's gangrene", J Korean Soc Coloproctol, 16, pp.309~315 (2000)
70. Park YB., "Necrotizing fasciitis", J Korean Surg Soc, 35, pp.619~625 (1988)
71. 김광민, "Fournier’s Gangrene 치료 경험과 예후 인자 분석", Annals of Coloproctolgy, 26(1), pp.29~33 (2010), 대한대장항문학회
72. 송상준, "하지에 발생한 I,II형 급성 괴사성 근막염", 대한정형외과학회지, 42(5), pp.636~643 (2007), 대한정형외과학회
73. 석지현, "Necrotizing Fasciitis versus Pyomyositis: Discrimination with Using MR Imaging", Korean Journal of Radiology, 10(2), pp.121~128 (2009), 대한영상의학회
74. Kim DM., "In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus", Antimicrob Agents Chemother, 49, pp.3489~3491 (2005)
75. Jeong HJ., "Prognostic factors in Fournier gangrene", Int J Urol, 12, pp.1041~1044 (2005)
76. 최성호, "지역사회 획득 괴사성 근막염의 임상적 특성과 원인균에 관한 연구", Infection and Chemotherapy, 44(3), pp.180~184 (2012), 대한감염학회[DOI]
77. Park KH., "Marine bacteria as a leading cause of necrotizing fasciitis in coastal areas of South Korea", Am J Trop Med Hyg, 80, pp.646~650 (2009)
78. Kim ES., "A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 60, pp.1108~1114 (2007), OXFORD UNIV PRESS
79. 김문석, "피부 및 연조직 감염에서의 항생제 내성 및 최신 치료", 대한내과학회지, 81(6), pp.699~707 (2011), 대한내과학회
80. Stoneback JW., "Diagnosis and management of necrotizing fasciitis", Orthopedics, 34, pp.196~ (2011)
81. Vinh DC., "Rapidly progressive soft tissue infections", Lancet Infect Dis, 5, pp.501~513 (2005)
82. Wang YS., "Staging of necrotizing fasciitis based on the evolving cutaneous features", Int J Dermatol, 46, pp.1036~1041 (2007)
83. Wysoki MG., "Necrotizing fasciitis : CT characteristics", Radiology, 203, pp.859~863 (1997)
84. Becker M., "Necrotizing fasciitis of the head and neck : role of CT in diagnosis and management", Radiology, 202, pp.471~476 (1997)
85. Saldana M., "Periorbital necrotizing fasciitis : outcomes using a CT-guided surgical debridement approach", Eur J Ophthalmol, 20, pp.209~214 (2010)
86. Schmid MR., "Differentiation of necrotizing fasciitis and cellulitis using MR imaging", AJR Am J Roentgenol, 170, pp.615~620 (1998)
87. Hopkins KL., "Gadolinium-DTPA-enhanced magnetic resonance imaging of musculoskeletal infectious processes", Skeletal Radiol, 24, pp.325~330 (1995)
88. Arslan A., "Necrotizing fasciitis : unreliable MRI findings in the preoperative diagnosis", Eur J Radiol, 36, pp.139~143 (2000)
89. Rahmouni A., "MR imaging in acute infectious cellulitis", Radiology, 192, pp.493~496 (1994)
90. Kim KT., "Can Necrotizing Infectious Fasciitis Be Differentiated from Nonnecrotizing Infectious Fasciitis with MR Imaging?", RADIOLOGY, 259(3), pp.816~824 (2011), RADIOLOGICAL SOC NORTH AMERICA
91. Yen ZS., "Ultrasonographic screening of clinically-suspected necrotizing fasciitis", Acad Emerg Med, 9, pp.1448~1451 (2002)
92. Wong CH., "The LRINEC(Laboratory Risk Indicator for Necrotizing Fasciitis)score : a tool for distinguishing necrotizing fasciitis from other soft tissue infections", Crit Care Med, 32, pp.1535~1541 (2004)
93. Tsai YH., "Laboratory indicators for early detection and surgical treatment of vibrio necrotizing fasciitis", Clin Orthop Relat Res, 468, pp.2230~2237 (2010)
94. Holland MJ., "Application of the Laboratory Risk Indicator in Necrotising Fasciitis(LRINEC)score to patients in a tropical tertiary referral centre", Anaesth Intensive Care, 37, pp.588~592 (2009)
95. Stamenkovic I., "Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy", N Engl J Med, 310, pp.1689~1693 (1984)
96. Majeski J., "Necrotizing fasciitis : improved survival with early recognition by tissue biopsy and aggressive surgical treatment", South Med J, 90, pp.1065~1068 (1997)
97. Wong CH., "Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality", J Bone Joint Surg Am, 85-A, pp.1454~1460 (2003)
98. Bilton BD., "Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study", Am Surg, 64, pp.397~400 (1998)
99. Elliott DC., "Necrotizing soft tissue infections. Risk factors for mortality and strategies for management", Ann Surg, 224, pp.672~683 (1996)
100. Voros D., "Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection", Br J Surg, 80, pp.1190~1191 (1993)
101. Mulla ZD., "Invasive group A streptococcal infections in Florida", South Med J, 96, pp.968~973 (2003)
102. Zimbelman J., "Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection", Pediatr Infect Dis J, 18, pp.1096~1100 (1999)
103. Darabi K., "Current usage of intravenous immune globulin and the rationale behind it : the Massachusetts General Hospital data and a review of the literature", Transfusion, 46, pp.741~753 (2006)
104. Kaul R., "Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group", Clin Infect Dis, 28, pp.800~807 (1999)
105. Norrby-Teglund A., "Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections", Scand J Infect Dis, 35, pp.683~689 (2003)
106. Cawley MJ., "Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis : case report and review", Pharmacotherapy, 19, pp.1094~1098 (1999)
107. Kaide CG., "Hyperbaric oxygen: applications in infectious disease", Emerg Med Clin North Am, 26, pp.571~595 (2008)
108. Demello FJ., "Comparative study of experimental Clostridium perfringens infection in dogs treated with antibiotics, surgery, and hyperbaric oxygen", Surgery, 73, pp.936~941 (1973)
109. Jallali N., "Hyperbaric oxygen as adjuvant therapy in the management of necrotizing fasciitis", Am J Surg, 189, pp.462~466 (2005)
110. Wilkinson D., "Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection", Arch Surg, 139, pp.1339~1345 (2004)
111. Escobar SJ., "Adjuvant hyperbaric oxygen therapy(HBO2)for treatment of necrotizing fasciitis reduces mortality and amputation rate", Undersea Hyperb Med, 32, pp.437~443 (2005)
112. George ME., "Hyperbaric oxygen does not improve outcome in patients with necrotizing soft tissue infection", Surg Infect(Larchmt), 10, pp.21~28 (2009)
113. Shupak A., "Necrotizing fasciitis : an indication for hyperbaric oxygenation therapy?", Surgery, 118, pp.873~878 (1995)
114. Riseman JA., "Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements", Surgery, 108, pp.847~850 (1990)
115. Sacks JJ., "Dog bites : how big a problem?", Inj Prev, 2, pp.52~54 (1996)
116. MacBean CE., "Animal and human bite injuries in Victoria, 1998-2004", Med J Aust, 186, pp.38~40 (2007)
117. Talan DA., "Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group", N Engl J Med, 340, pp.85~92 (1999)
118. Goldstein EJ., "New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds", J Med Microbiol, 47, pp.95~97 (1998)
119. Goldstein DJ., "Outpatient pacemaker procedures in orally anticoagulated patients", Pacing Clin Electrophysiol, 21, pp.1730~1734 (1998)
120. Stumvoll M., "Type 2 diabetes : principles of pathogenesis and therapy", Lancet, 365, pp.1333~1346 (2005)
121. Talan DA., "Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments", Clin Infect Dis, 37, pp.1481~1489 (2003)
122. Vidmar L., "Transmission of HIV-1 by human bite", Lancet, 347, pp.1762~ (1996)
123. Dusheiko GM., "Hepatitis C virus transmitted by human bite", Lancet, 336, pp.503~504 (1990)
124. Davis LG., "Horizontal transmission of hepatitis B virus", Lancet, 1, pp.889~893 (1989)
125. Fiumara NJ., "Primary syphilis following a human bite", Sex Transm Dis, 8, pp.21~22 (1981)
126. Lipsky BA., "A report from the international consensus on diagnosing and treating the infected diabetic foot", Diabetes Metab Res Rev, 20(Suppl 1), pp.S68~S77 (2004)
127. Lipsky BA., "Diagnosis and treatment of diabetic foot infections", Clin Infect Dis, 39, pp.885~910 (2004)
128. Lavery LA., "Validation of the Infectious Diseases Society of America's diabetic foot infection classification system", Clin Infect Dis, 44, pp.562~565 (2007)
129. Slater RA., "Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone", Diabet Med, 21, pp.705~709 (2004)
130. Sapico FL., "The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features", Rev Infect Dis, 6, pp.S171~S176 (1984)
131. Wheat LJ., "Diabetic foot infections. Bacteriologic analysis", Arch Intern Med, 146, pp.1935~1940 (1986)
132. Petersen PJ., "In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections", Diagn Microbiol Infect Dis, 66, pp.407~418 (2010)
133. 서유빈, "감염성 당뇨 족부 궤양: 심부 조직 배양 검사 결과에 기초한 원인균 분석", Infection and Chemotherapy, 39(5), pp.237~242 (2007), 대한감염학회
134. Hartemann-Heurtier A., "Diabetic foot ulcer and multidrug-resistant organisms : risk factors and impact", Diabet Med, 21, pp.710~715 (2004)
135. Kim H., "Anaerobic bacteria isolated from diabetic foot lesions", J Korean Diabetes Assoc, 19, pp.305~312 (1995)
136. Ge Y., "Microbiological profile of infected diabetic foot ulcers", Diabet Med, 19, pp.1032~1034 (2002)
137. Hunt JA., "Foot infections in diabetes are rarely due to a single microorganism", Diabet Med, 9, pp.749~752 (1992)
138. Chantelau E., "Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes : a controlled trial", Diabet Med, 13, pp.156~159 (1996)
139. Hirschl M., "Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone", Chemotherapy, 38, pp.275~280 (1992)
140. Lipsky BA., "Outpatient management of uncomplicated lower-extremity infections in diabetic patients", Arch Intern Med, 150, pp.790~797 (1990)
141. Lipsky BA., "Evidence-based antibiotic therapy of diabetic foot infections", FEMS Immunol Med Microbiol, 26, pp.267~276 (1999)
142. Raymakers JT., "The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb", Diabet Med, 18, pp.229~234 (2001)
143. Duckworth C., "Tissue penetration of clindamycin in diabetic foot infections", J Antimicrob Chemother, 31, pp.581~584 (1993)
144. Kuck EM., "Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections", Foot Ankle Int, 19, pp.38~40 (1998)
145. Müller M., "Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients", Antimicrob Agents Chemother, 43, pp.2056~2058 (1999)
146. Seabrook GR., "Comparison of serum and tissue antibiotic levels in diabetes-related foot infections", Surgery, 110, pp.671~676 (1991)
147. Nelson EA., "Systematic review of antimicrobial treatments for diabetic foot ulcers", Diabet Med, 23, pp.348~359 (2006)
148. Frykberg RG., "Diabetic foot disorders. A clinical practice guideline (2006 revision)", J Foot Ankle Surg, 45(5 Suppl), pp.S1~S66 (2006)
149. Lipsky BA., "Antibiotic therapy for diabetic foot infections : comparison of two parenteral-to-oral regimens", Clin Infect Dis, 24, pp.643~648 (1997)
150. Grayson ML., "Use of ampicillin", sulbactam versus imipenem, Clin Infect Dis, pp.1994, 18[DOI]
151. Scher KS., "The septic foot in patients with diabetes", Surgery, 104, pp.661~666 (1988)
152. Tan JS., "Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation?", Clin Infect Dis, 23, pp.286~291 (1996)
153. Piaggesi A., "Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers : a randomized trial", Diabet Med, 15, pp.412~417 (1998)
154. Durham JR., "Open transmetatarsal amputation in the treatment of severe foot infections", Am J Surg, 158, pp.127~130 (1989)
155. Benton GS., "Cost effectiveness of early digit amputation in the patient with diabetes", Surg Gynecol Obstet, 161, pp.523~524 (1985)
156. Wade JC., "Management of infection in patients with acute leukemia", Hematol Oncol Clin North Am, 7, pp.293~315 (1993)
157. Pizzo PA., "Management of fever in patients with cancer and treatment-induced neutropenia", N Engl J Med, 328, pp.1323~1332 (1993)
158. Donowitz GR., "Fever in the compromised host", Infect Dis Clin North Am, 10, pp.129~148 (1996)
159. Wolfson JS., "Dermatologic manifestations of infections in immunocompromised patients", Medicine(Baltimore), 64, pp.115~133 (1985)
160. Wolfson JS., "Dermatologic manifestations of infection in the compromised host", Annu Rev Med, 34, pp.205~217 (1983)
161. Hughes WT., "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer", Clin Infect Dis, 34, pp.730~751 (2002)
162. Wingard JR., "Differences between first and subsequent fevers during prolonged neutropenia", Cancer, 59, pp.844~849 (1987)
163. Lopez FA., "Dermatologic infections in the immunocompromised (non-HIV) host", Infect Dis Clin North Am, 15, pp.671~702 (2001)
164. Glauser M., "Empiric therapy of bacterial infections in patients with severe neutropenia", Diagn Microbiol Infect Dis, 31, pp.467~472 (1998)
165. Goodrich JM., "Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation", J Infect Dis, 164, pp.731~740 (1991)
166. Freifeld AG., "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america", Clin Infect Dis, 52, pp.56~93. (2011)
167. 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회

관련 논문AI추천